
---
markmap:
  colorFreezeLevel: 6
---

## Drug Dosing

- ### Principles
  - Loading Dose
    - Rapid achievement of target concentration (Css)
    - Formula: LD = (Target Cp * Vd) / Bioavailability
  - Maintenance Dose
    - Maintain Css by replacing amount eliminated
    - Formula: MD = (Target Cp * Clearance * Dosing Interval) / Bioavailability
    - **Steady State:** Rate in = Rate out (achieved in ~4-5 half-lives)
- ### Pharmacokinetic Parameters
  - **Volume of Distribution (Vd)**
    - Relates amount of drug in body to concentration in blood/plasma
    - Vd = Dose / Initial Plasma Concentration
    - Affects Loading Dose
  - **Clearance (CL)**
    - Volume of plasma cleared of drug per unit time
    - CL = Rate of Elimination / Plasma Concentration
    - Primary organs: Kidney, Liver
    - Affects Maintenance Dose
  - **Half-life (t½)**
    - Time for plasma concentration to reduce by half
    - t½ = (0.693 * Vd) / CL
    - Determines time to steady state and dosing interval
  - **Bioavailability (F)**
    - Fraction of administered dose reaching systemic circulation unchanged
    - Influenced by Absorption, First Pass Metabolism
- ### Factors Affecting Dosing
  - Patient Age (Pediatric, Geriatric)
  - Body Weight / Surface Area
  - **Organ Function (Renal, Hepatic)**
  - **Comorbidities**
  - **Drug Interactions**
  - Pharmacogenomics
  - Therapeutic Objective
- ### Dosing in Special Populations
  - **Renal Impairment**
    - Primary focus: Drugs eliminated by kidney
    - Assess with CrCl (**Cockcroft-Gault Formula**) or GFR
    - **Dose Adjustment:** Decrease maintenance dose OR increase dosing interval
    - Consider hemodialysis impact
  - **Hepatic Impairment**
    - Primary focus: Drugs metabolized by liver
    - Assess with **Child-Pugh Score** or MELD score (for cirrhosis)
    - Complex; depends on metabolism type, hepatic blood flow, protein binding
    - Often reduce maintenance dose
  - **Pediatrics**
    - Age-dependent changes in absorption, distribution, metabolism, excretion
    - Often dose by weight (mg/kg) or BSA (mg/m²)
  - **Geriatrics**
    - Decreased lean body mass, increased fat (affects Vd)
    - Decreased renal/hepatic function
    - Polypharmacy, increased sensitivity
  - **Obesity**
    - Vd changes for lipophilic vs. hydrophilic drugs
    - Dosing based on ideal, adjusted, or total body weight
  - Critical Illness
    - Sepsis, shock, organ failure affect all PK parameters
    - Augmented renal clearance in young critical patients
- ### Therapeutic Drug Monitoring (TDM)
  - When needed: Narrow therapeutic index, significant PK variability, desired effect difficult to monitor, suspect toxicity or non-compliance
  - **Common Drugs:**
    - **Aminoglycosides:** Peak & Trough
    - **Vancomycin:** Trough (AUC-guided becoming more common)
    - **Digoxin:** Trough
    - **Phenytoin:** Free vs. Total (Saturable kinetics/Zero-order)
    - **Lithium:** Trough
    - Theophylline, Cyclosporine, Tacrolimus, Warfarin (INR)
- ### Key Calculations / Formulas (INICET Buzz)
  - **Cockcroft-Gault:** CrCl = [(140-Age) * Weight (kg)] / (Serum Creatinine * 72) (*0.85 for females*)
  - Loading Dose = Vd * Target Cp
  - Maintenance Dose = CL * Target Cp
  - Css = (Dose Rate) / CL
- ### INICET Buzzwords
  - **Narrow Therapeutic Index**
  - **First Pass Metabolism**
  - **Protein Binding (Alpha-1 acid glycoprotein, Albumin)**
  - **Bioavailability (F)**
  - **Vd, CL, t½**
  - **Steady State**
  - **AUC (Area Under the Curve)**
  - **Cmax, Cmin, Trough, Peak**
  - **Saturation Kinetics (Zero-Order)** - eg. Phenytoin, Ethanol, Aspirin (high doses)
  - **First-Order Kinetics** - Majority of drugs
  - **Prodrug**
  - **Renal Clearance**
  - **Hepatic Clearance**
  - **Child-Pugh Score**
  - **Augmented Renal Clearance**
  - **TDM**
  - **Population Pharmacokinetics**
